Scarica l'app Stockscreener
0.8156
7.32%
-0.0644
Dopo l'orario di chiusura:
.82
0.0044
+0.54%
Precedente Chiudi:
$0.88
Aprire:
$0.8699
Volume 24 ore:
1.17M
Relative Volume:
1.71
Capitalizzazione di mercato:
$38.12M
Reddito:
-
Utile/perdita netta:
$-37.65M
Rapporto P/E:
-0.4884
EPS:
-1.67
Flusso di cassa netto:
$-24.14M
1 W Prestazione:
-25.85%
1M Prestazione:
-5.92%
6M Prestazione:
-30.88%
1 anno Prestazione:
-45.63%
Intervallo 1D:
$0.7888
$0.8699
Intervallo di 1 settimana:
$0.7888
$1.1499
Portata 52W:
$0.485
$4.28
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile
Nome
Reviva Pharmaceuticals Holdings Inc
Settore
Industria
Telefono
(408) 501-8881
Indirizzo
10080 N WOLFE ROAD, CUPERTINO
Confronta RVPH con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RVPH
Reviva Pharmaceuticals Holdings Inc
|
0.8156 | 51.41M | 0 | -37.65M | -24.14M | -1.67 |
|
ONC
Beone Medicines Ltd Adr
|
251.72 | 25.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.48 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3401 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.81 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.86 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-09-20 | Iniziato | ROTH MKM | Buy |
| 2023-06-08 | Iniziato | The Benchmark Company | Speculative Buy |
| 2022-01-24 | Iniziato | H.C. Wainwright | Buy |
Reviva Pharmaceuticals Holdings Inc Borsa (RVPH) Ultime notizie
Reviva reports positive year-long schizophrenia drug study By Investing.com - Investing.com South Africa
Reviva Pharmaceuticals Holdings, Inc. Announces Positive Full Dataset for 1-Year Phase 3 Recover Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia - marketscreener.com
Reviva Reports Positive Full Dataset For Phase 3 RECOVER OLE Study Of Brilaroxazine In Schizophrenia - Nasdaq
Reviva reports positive year-long schizophrenia drug study - Investing.com Australia
Reviva Pharmaceuticals (RVPH) Unveils Promising Phase 3 Brilaroxazine Study Results | RVPH Stock News - GuruFocus
Reviva Pharmaceuticals Completes Phase 3 Study for Schizophrenia - TipRanks
Reviva Announces Positive Full Dataset for 1-Year Phase 3 - GlobeNewswire
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Shares Sold by Millennium Management LLC - Defense World
Reviva Pharmaceuticals Launches $50M At-Market Offering - TipRanks
Reviva Pharmaceuticals Holdings IncEnters Into At Market Issuance Sales AgreementSEC Filing - marketscreener.com
What is Zacks Small Cap’s Estimate for RVPH Q2 Earnings? - Defense World
Roth Capital Issues Positive Forecast for RVPH Earnings - Defense World
D. Boral Capital Lowers Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target to $3.00 - Defense World
Reviva Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Reviva stock target cut to $3 on cash concerns, retains Buy rating - Investing.com Australia
Spotify To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday - NewsBreak: Local News & Alerts
Reviva to Participate in Upcoming Investor Conferences in May 2025 - GlobeNewswire
Late-Stage CNS Drug Developer Reviva Opens Access to Management at Benchmark and Lytham Conferences - Stock Titan
Reviva Pharmaceuticals (RVPH): Analyst Maintains Buy Rating, Low - GuruFocus
Reviva Pharmaceuticals (RVPH) Sees Price Target Reduction Amid Funding Concerns | RVPH Stock News - GuruFocus
Reviva Pharmaceuticals (RVPH): Analyst Maintains Buy Rating, Lowers Price Target | RVPH Stock News - GuruFocus
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Reviva Pharmaceuticals (RVPH) Advances Brilaroxazine Program Tow - GuruFocus
Reviva Pharmaceuticals (RVPH) Advances Brilaroxazine Program Towards Approval | RVPH Stock News - GuruFocus
Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Major Milestone: 446 Patients Complete Reviva's Schizophrenia Drug Trial, Full Results Expected Q2 2025 - Stock Titan
Reviva to Participate in the A.G.P. Healthcare Company Showcase - GlobeNewswire
Tower Research Capital LLC TRC Has $48,000 Stock Holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals (RVPH) Expected to Announce Earnings on Tuesday - Defense World
Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Grows By 30.5% - Defense World
Geode Capital Management LLC Grows Position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) - Defense World
Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight - GlobeNewswire Inc.
Reviva to Participate in the Citizens Life Sciences Conference - GlobeNewswire
Reviva Pharma CEO Takes Center Stage: Key Updates Coming at Major Life Sciences Conference - Stock Titan
Gaining Ground: Reviva Pharmaceuticals Holdings Inc (RVPH) Closes Lower at 0.86, Down -4.98 - DWinneX
Market Update: American Rebel Holdings Inc (AREB) Sees Negative Movement, Closing at 3.85 - DWinneX
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire
D. Boral Capital Reiterates “Buy” Rating for Reviva Pharmaceuticals (NASDAQ:RVPH) - Defense World
Reviva Pharmaceuticals Holdings Inc Inc. (RVPH) Price Performance: The Role of Supply and Demand - investchronicle.com
Reviva to Present Late-Breaking Poster on the RECOVER - GlobeNewswire
Major Phase 3 Breakthrough: Reviva Unveils 12-Month Schizophrenia Treatment Data at ASCP 2025 - Stock Titan
Investing in Reviva Pharmaceuticals Holdings Inc (RVPH) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - uspostnews.com
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Reviva Pharmaceuticals (RVPH) to Release Earnings on Monday - Defense World
RVPH: M&A Deals Highlight Brilaroxazine Value - MSN
What is Roth Capital’s Forecast for RVPH Q1 Earnings? - Defense World
Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results - streetwisereports.com
Reviva Pharmaceuticals Holdings Inc. (RVPH) reports earnings - qz.com
Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target Lowered to $8.00 at D. Boral Capital - Defense World
Reviva Pharmaceuticals Reports 2024 Financial Results - TipRanks
RVPH stock touches 52-week low at $0.6 amid market challenges - Investing.com Australia
Reviva Pharmaceuticals Holdings Inc Azioni (RVPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):